Gene therapy biotech secures FDA alignment for Huntington's disease BLA submission.

uniQure posts a wider Q2 2026 loss as revenues missed estimates, but regulatory progress for AMT-130 and a cash runway into 2030 keep its pipeline in focus.

Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls

Wall Street analysts reshuffled their bets on Thursday as geopolitical fires, a Fed dissent surprise, and a brutal semiconductor selloff forced some major rating reversals across insurance, gaming, tech, and energy stocks.

uniQure NV (QURE) reports steady revenue growth and regulatory progress, while navigating high R&D expenses and operational hurdles.

uniQure (NASDAQ:QURE) said it has aligned with the U.S. Food and Drug Administration on a potential accelerated-approval pathway for AMT-130, its investigational gene therapy for Huntington's disease, and remains on track to submit a biologics license application in the third quarter of 2026. Chief

If approved, uniQure’s AMT-130 would be the first disease-modifying treatment for the inherited neurodegenerative disorder.

uniQure (QURE) delivered earnings and revenue surprises of -50.62% and -17.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

uniQure’s stock has delivered a very large 301.7% return over the past three years. However, on Simply Wall St’s checks it still screens as expensive overall, with a low value score and market multiples that lean toward an overvalued verdict. Over the last three years, uniQure has returned 301.7%, which puts extra focus on whether recent gains leave enough room for mistakes in the story from here. For a research stage biotech like uniQure, future cash needs and the timing of potential...

QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.